Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06649110 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
A Phase 1 study of Healthy Volunteers, Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 232
- Enrollment target
- 20
- Study locations
NCT06649110: Recruiting Phase 1 study of Healthy Volunteers, Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals.
NCT06649110 is a Phase 1 study of Healthy Volunteers, Pulmonary Arterial Hypertension that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 232 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (287% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06649110, a Phase 1 study of Healthy Volunteers, Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 232 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Primary Outcome
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations and adverse events up to and including the end-of-study visit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LTP
Study Locations (20)
Other
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Heidelberg
- Novartis Investigative Site - Thessaloniki
New South Wales
- Novartis Investigative Site - Camperdown
- Novartis Investigative Site - Darlinghurst
- Novartis Investigative Site - New Lambton Heights
California
- Stanford Medical Center - Stanford
Colorado
- Univ Colorado Hospital - Aurora
Kansas
- U of Kansas Medical Center - Kansas City
Kentucky
- Norton Infectious Diseases Specialists - Louisville
Massachusetts
- Tufts Medical Center - Boston
Oregon
- Summit Health Eastside Clinic - Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT06649110 shows while recruiting
NCT06649110 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (287% higher).
The record links to 1 condition, with Healthy Volunteers, Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06649110 names 20 study sites across 15 states, led by Other, New South Wales, California.
Frequently Asked Questions
What is clinical trial NCT06649110 about?
NCT06649110 is a clinical study titled "A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)". A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
What is the current status of trial NCT06649110?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2024-10-24. Estimated completion is 2028-12-31.
What conditions does trial NCT06649110 study?
This clinical trial studies the following conditions: Healthy Volunteers, Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06649110?
The interventions under investigation include: Placebo (DRUG), LTP (DRUG).
Who is sponsoring clinical trial NCT06649110?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06649110 being conducted?
This trial has 20 study locations across California, Colorado, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06649110's enrollment target sits among peer trials
232 216th of 2000 higher than 1,784 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI